GenEvolution

Executive Summary

GenEvolution is a French Contract Research Organization (CRO) founded in 2018, specializing in in vitro genetic toxicology and toxicology testing services. The company provides GLP and ISO 17025 compliant assays, including Ames tests, micronucleus assays, and phototoxicity studies, primarily for the pharmaceutical, cosmetic, and chemical industries. By leveraging human cell and reconstructed tissue models combined with advanced analytical technologies, GenEvolution helps clients predict carcinogenic risk without animal testing, aligning with evolving regulatory preferences for non-animal methods. The company operates from Paris and serves a growing European market, capitalizing on the increasing demand for reliable in vitro toxicology services amid stricter chemical safety regulations (e.g., REACH) and the cosmetics animal testing ban. GenEvolution's focus on compliance and reproducibility positions it as a trusted partner for R&D and regulatory submissions, though its private status limits visibility into financial performance. The CRO market is fragmented, but GenEvolution's niche specialization and quality certifications provide competitive advantages. Growth prospects depend on securing large contracts and expanding service offerings to capture a larger share of the global in vitro toxicology market, projected to grow at a CAGR of ~10% through 2030.

Upcoming Catalysts (preview)

• Q4 2026Major contract win with top-10 pharmaceutical or cosmetic company40% success
• Q2 2027Expansion of service portfolio to include new OECD Guideline assays (e.g., in vitro skin sensitization)60% success
• Q3 2027Partnership or acquisition by a larger CRO seeking in vitro toxicology capabilities30% success